πŸ‡ΊπŸ‡Έ FDA
Patent

US 9637535

IL-33 antagonists and uses thereof

granted A61KA61K38/00A61K38/17

Quick answer

US patent 9637535 (IL-33 antagonists and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K38/00, A61K38/17, A61K38/20, A61K39/3955